SEL120-34A monohydrochloride 是一种选择性的,ATP-竞争性的CDK8抑制剂,对 CDK8/CycC 和 CDK19/CycC 复合物的IC50值分别为 4.4 nM 和 10.4 nM,对 CDK8 的Kd值为 3 nM。SEL120-34A monohydrochloride 对 CDK9 的作用很弱,计算的IC50值为 1070 nM,而对 CDK1、2、4、6、5、7 等无作用。SEL120-34A monohydrochloride 能够抑制 STAT1 S727 和 STAT5 S726 的磷酸化。具有抗肿瘤活性。
生物活性 | SEL120-34A monohydrochloride is an ATP-competitive and selectiveCDK8inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes withIC50s of 4.4 nM and 10.4 nM, respectively, with aKdof 3 nM forCDK8. SEL120-34A monohydrochloride weakly inhibitsCDK9(calculatedIC50=1070 nM), but shows no obvious activity againstCDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 andSTAT5S726[1]. Has anti-tumor activity[1]. |
IC50& Target[1] | CDK8/CycC 4.4 nM (IC50) | CDK19/CycC 10.4 nM (IC50) | CDK9/cycT 1070 nM (IC50) |
|
体外研究 (In Vitro) | SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kdof 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7[1]. SEL120-34A (1.6 nM-5 μM) inhibits the growth of STAT5 S726 positive KG-1 AML cells, but is not cytotoxic to S726 negative MOLM13 AML cells[1]. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726, decreases IRF9 and STAT1 mRNA expression and mitogen-induced IER expression[1].
|
体内研究 (In Vivo) | SEL120-34A monohydrochloride (30, 60 mg/kg, p.o. once every day) inhibits growth of AML tumors in a dose-dependent manner in SCID mice after treatment for 17 days[1].
|
分子量 | |
性状 | |
Formula | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: H2O : 50 mg/mL(110.96 mM;Need ultrasonic) DMSO : 16.67 mg/mL(37.00 mM;ultrasonic and warming and heat to 60℃) 配制储备液 1 mM | 2.2193 mL | 11.0963 mL | 22.1926 mL | 5 mM | 0.4439 mL | 2.2193 mL | 4.4385 mL | 10 mM | 0.2219 mL | 1.1096 mL | 2.2193 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 14.29 mg/mL (31.71 mM); Clear solution; Need ultrasonic and warming and heat to 60℃ 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 1.67 mg/mL (3.71 mM); Clear solution
此方案可获得 ≥ 1.67 mg/mL (3.71 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 1.67 mg/mL (3.71 mM); Clear solution
此方案可获得 ≥ 1.67 mg/mL (3.71 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 1.67 mg/mL (3.71 mM); Clear solution
此方案可获得 ≥ 1.67 mg/mL (3.71 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|